In particular, HDAC2 overexpression has been described in ovarian cancer [42] and has been associated with aggressive cutaneous T cell lymphoma [43], advanced-stage gastric [44], colorectal cancer [45], and shorter disease-free survival of prostate cancer patients [46]. This evidence concerns the gene HDAC2 and prostate cancer.